How do you approach patients with stage III unresectable, combined histology NSCLC/SCLC?
Following chemoradiation, would you consider maintenance durvaluamb as for NSCLC even given the SCLC component?
Answer from: Medical Oncologist at Academic Institution
This is a difficult question and I am not sure there is a "right answer". I would probably discuss with my pathologist what seems to be the more dominant histology if there is one. I would choose cisplatin with etoposide rather than carboplatin with paclitaxel as the chemotherapy backbone due to the...
Comments
Medical Oncologist at University of Pittsburgh I agree. A concurrent chemoradiotherapy backbone w...
I agree. A concurrent chemoradiotherapy backbone w...